Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A4 | P31645 | 2/20 | 0.34 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.34 |
| ▸ | HTR2A | P28223 | 1/20 | 0.34 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.34 |
| ▸ | DRD3 | P35462 | 1/20 | 0.34 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.34 |
| ▸ | HTR2B | P41595 | 1/20 | 0.34 |
| ▸ | CTSL | P07711 | 1/20 | 0.31 |
| ▸ | SLC5A2 | P31639 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25668477 | 0.90 | SIGMAR1 (0.34) | SLC6A4SIGMAR1LMNAMAPTADRA2C | |
| SCHEMBL25569522 | 0.88 | SLC5A2 (0.32) | SLC6A4LMNAMAPTCTSLSLC5A2 | |
| SCHEMBL25569513 | 0.81 | SIGMAR1 (0.45) | SLC6A4SIGMAR1LMNAMAPTADRA2C | |
| SCHEMBL25569518 | 0.81 | CTSL (0.32) | SLC6A4CTSLSLC5A2 | |
| SCHEMBL25569515 | 0.81 | SLC6A4 (0.36) | SLC6A4CTSLSLC5A2 | |
| SCHEMBL25569657 | 0.80 | SLC6A4 (0.46) | SLC6A4CTSL | |
| SCHEMBL25569514 | 0.78 | SLC6A4 (0.36) | SLC6A4CTSLSLC5A2 | |
| SCHEMBL25569519 | 0.78 | SLC5A2 (0.32) | SLC6A4LMNAMAPTCTSLSLC5A2 | |
| SCHEMBL25569516 | 0.78 | SLC6A4 (0.36) | SLC6A4LMNAMAPTCTSLSLC5A2 | |
| SCHEMBL25668478 | 0.78 | ALDH1A1 (0.30) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230159487-A1 | ADVANTAGEOUS BENZOTHIOPHENE COMPOSITIONS FOR MENTAL DISORDERS OR ENHANCEMENT | TACTOGEN INC (US) | 2023-05-25 | — | — | US | disclosed |
| US-20230159487-A1 | ADVANTAGEOUS BENZOTHIOPHENE COMPOSITIONS FOR MENTAL DISORDERS OR ENHANCEMENT | TACTOGEN INC (US) | 2023-05-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230159487-A1 | ADVANTAGEOUS BENZOTHIOPHENE COMPOSITIONS FOR MENTAL DISORDERS OR ENHANCEMENT | SLC6A3, CREBBP, SLC1A2 | SLC6A4 21/4885SIGMAR1 3275/4885LMNA 4660/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.